PAVmed (NASDAQ:PAVM) Upgraded to Strong-Buy at Zacks Research

PAVmed (NASDAQ:PAVM) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

Several other brokerages have also commented on PAVM. Weiss Ratings reissued a “sell (d)” rating on shares of PAVmed in a report on Wednesday. Ascendiant Capital Markets boosted their price objective on PAVmed from $19.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, October 6th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

PAVmed Trading Down 0.1%

Shares of NASDAQ PAVM opened at $0.49 on Thursday. PAVmed has a 12 month low of $0.30 and a 12 month high of $1.25. The firm has a market capitalization of $10.71 million, a price-to-earnings ratio of 0.42 and a beta of 1.07. The business has a 50-day moving average of $0.45 and a 200-day moving average of $0.58.

Institutional Trading of PAVmed

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC increased its position in PAVmed Inc. (NASDAQ:PAVM) by 392.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,676 shares of the company’s stock after buying an additional 41,990 shares during the quarter. Jane Street Group LLC owned 0.31% of PAVmed worth $32,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 19.93% of the stock is owned by hedge funds and other institutional investors.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.